ASCO GU 2019: Pembrolizumab Plus Axitinib Extended Overall Survival and Progression-Free Survival Versus Current Standard Treatment for Advanced Kidney Cancer
Results from the randomized, phase III KEYNOTE-426 clinical trial show that first-line therapy with a combination of the PD-1 targeted…
Mobile app could help reduce cancer-related fatigue
Tired of Cancer B.V. has launched its research study into the effectiveness of the Untire mobile app and reducing cancer-related fatigue (CRF),…
Recent Videos
-
ASCO GU 2019 VIDEO: Genitourinary Cancers Symposium Presscast
-
Nobel Prize awarded “for discovery of cancer therapy by inhibition of negative immune regulation”
-
-
Jury finds Monsanto liable in the first Roundup cancer trial – here’s what could happen next
-
Killer immunotherapy—fighting cancer with genetic engineering
-
-
-
-
-
Elephant genes suppress tumours. Could studying this help us prevent cancer?
The genetics and ageing rate of elephants could hold clues to helping us find better ways to fight cancer and…
‘Cellular barcoding’ reveals how breast cancer spreads
A cutting-edge technique called cellular barcoding has been used to tag, track and pinpoint cells responsible for the spread of…
WE CAN HELP CONNECT YOU
Hypofractionated radiotherapy should be considered new practice standard for men with low-risk prostate cancer
- ASCO GU 2019: Phase II Trial Shows Novel, Radiolabeled PSMA-Targeted Treatment Provides High Response Rates in Men With Metastatic Prostate Cancer
- ASCO GU 2019: Preliminary results from a phase II GALAHAD study in adults with metastatic castration-resistant prostate cancer and DNA repair pathway defects
- ASCO GU 2019: Immunotherapy combination generates responses against castration-resistant metastatic prostate cancer
